[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342202-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-342202-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","recurrence-after-primary-salivary-gland-carcinoma-frequency-survival-and-risk-factors","Recurrence after primary salivary gland carcinoma - Frequency, survival, and risk factors","","Primary salivary gland carcinomas are rare neoplasms that create major therapeutic challenges, especially when tumors recur. This study evaluates the incidence and anatomical distribution of recurrence, identifies risk factors, and quantifies survival outcomes. Data from 318 patients treated for salivary gland carcinoma between 1992 and 2020 were analyzed using Kaplan–Meier survival methods and uni- and multivariate statistical models. Recurrent disease occurred in 21.7% after a mean of 38.2 months; 5-year overall survival and disease-free survival were reported as 67% and 54%. Independent recurrence factors included positive resection margins, vascular invasion, and primary tumor location.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/recurrence-after-primary-salivary-gland-carcinoma-frequency-survival-and-risk-factors/342202/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/recurrence-after-primary-salivary-gland-carcinoma-frequency-survival-and-risk-factors/342202.png","ImageObject",300,407,{"name":42,"@type":43},"Clementine","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the study’s main goal regarding salivary gland carcinoma?","Question",{"text":63,"@type":64},"To determine how often and where tumor recurrence occurred, which factors were associated with recurrence, and what survival outcomes were observed.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was recurrence defined and categorized in this analysis?",{"text":68,"@type":64},"Recurrence was defined as recurrent disease occurring more than 6 months after initial diagnosis and categorized into locoregional and distant recurrence; relapse within 6 months was classified as residual disease.",{"name":70,"@type":61,"acceptedAnswer":71},"Which factors were independently associated with recurrence?",{"text":72,"@type":64},"Multivariate analysis identified positive resection margins, vascular invasion, and tumor localization in the submandibular gland and small salivary glands as independent recurrence factors.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342202,1791110441,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","DOI: 10.1002/hed.27880  \nORIGINAL ARTICLE  \nRecurrence after primary salivary gland carcinoma: Frequency, survival, and risk factors  \nLisa Nachtsheim MD 1  | L. Jansen 1 | S. Shabli MD 1 | C. Arolt MD 2 |  \nA. Quaas MD 2 | J. P. Klussmann MD 1 | M. Mayer MD 1 | P. Wolber MD 1  \n1Department of  \nOtorhinolaryngology – Head and Neck Surgery, Medical Faculty, University of Cologne, Cologne, Germany  \n2Institute of Pathology, Medical Faculty, University of Cologne, Cologne, Germany  \nCorrespondence  \nLisa Nachtsheim, Department of Otorhinolaryngology – Head and Neck Surgery, Medical Faculty, University of Cologne, Cologne, Germany.  \nEmail: [lisa.nachtsheim@uk-koeln.de](lisa.nachtsheim@uk-koeln.de)  \nSection Editor: Patrick Ha  \nAbstract  \nBackground: Primary salivary gland carcinomas (SGC) are rare neoplasms that present therapeutic challenges especially in recurrent tumors. The aim of this study was to investigate the incidence and distribution of tumor recurrence, associated risk factors, and survival.  \nMethods: This analysis includes data from 318 patients treated for SGC between 1992 and 2020 . Survival analysis was performed using the Kaplan– Meier method. Univariate and multivariate analyses were used to identify risk factors associated with recurrence.  \nResults: 21.7% of the patients developed recurrent disease after a mean of 38.2 months. In multivariate analysis, positive-resection margins, vascular invasion, and tumor localization in the submandibular gland and small salivary glands were independent factors for recurrence. The 5-year overall survival was 67%, the 5-year disease-free survival was 54% .  \nConclusion: Tumor recurrence in SGC occurred in one out of five patients. In highly aggressive entities and patients with risk factors, treatment intensification should be considered.  \nKEYWOR DS  \nrecurrence, risk factors, salivary gland cancer, salivary gland neoplasms, survival  \n1 | INTRODUCTION  \nSalivary gland carcinomas (SGC) are a rare group of cancers in the head and neck region with a low incidence of \u003C1/100 000 . 1,2 The latest classification of the World Health Organization (WHO) recognizes more than 20 different entities with diverse biological behavior and clinical outcome. 3,4 Most SGC arise in the parotid gland and  \nM. Mayer and P. Wolber contributed equally to this study.  \nless frequently in the submandibular, sublingual, or the minor salivary glands of the oral mucosa.2,5,6  \nFor primary tumors, surgical resection remains the mainstay in the treatment of SGC. However, recurrent and unresectable SGC often require a multifaceted treatment scenario.7 Some authors report an incidence of local recurrences of up to 50% in patients with SGC, and even late recurrences after more than 5 years are not uncommon.5,8–10 Recurrences are characterized by the heterogeneity, different biological behavior, and aggressiveness of the different SGC entities. Up to  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.  \n© 2024 The Author(s). Head & Neck published by Wiley Periodicals LLC.  \n15%–20% of SGC develop distant metastases, which are more frequently found in high-grade tumors and those arising from the minor salivary glands.11,12 Especially in patients with adenoid cystic carcinoma (AdCC), the development of lung metastases after more than 5 years is not uncommon.9,10  \nSince response rates to radiation therapy, chemotherapy, and/or targeted therapy are generally low, treatment of recurrent tumors presents a particular therapeutic challenge.5 Overall survival (OS) has been shown to be significantly lower in recurrent SGC, particularly in late recurrences, andrecurrent disease is therefore associated with a poor prognosis.10,11 Since data on SGC recurrence and its prognostic factors are","cbCaimxh183pvLE4","https://ap.wps.com/l/cbCaimxh183pvLE4","pdf",1110242,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction\n# Materials and Methods\n## Patients\n## Statistical analysis","[{\"question\":\"What was the study’s main goal regarding salivary gland carcinoma?\",\"answer\":\"To determine how often and where tumor recurrence occurred, which factors were associated with recurrence, and what survival outcomes were observed.\"},{\"question\":\"How was recurrence defined and categorized in this analysis?\",\"answer\":\"Recurrence was defined as recurrent disease occurring more than 6 months after initial diagnosis and categorized into locoregional and distant recurrence; relapse within 6 months was classified as residual disease.\"},{\"question\":\"Which factors were independently associated with recurrence?\",\"answer\":\"Multivariate analysis identified positive resection margins, vascular invasion, and tumor localization in the submandibular gland and small salivary glands as independent recurrence factors.\"}]","Recurrence after primary salivary gland carcinoma - Frequency, survival, and risk factors | PDF",1790045755,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7de46e0a0f8565e9912a01d962212f6b.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/41696be2bf5a319722a0e12543f70dc0.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ea3d058adad2b0528c17a81474b54368.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3108f4c0582daf21b3789006c9ddfe40.webp",980,1287]